Jason Gerberry
Stock Analyst at B of A Securities
(3.62)
# 847
Out of 4,712 analysts
150
Total ratings
55.24%
Success rate
3.8%
Average return
Main Sectors:
Stocks Rated by Jason Gerberry
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXEL Exelixis | Downgrades: Neutral | $35 → $39 | $34.03 | +14.60% | 2 | Dec 17, 2024 | |
| BLUE bluebird bio | Downgrades: Neutral | $60 → $10 | $8.78 | +13.90% | 8 | Nov 15, 2024 | |
| ACLX Arcellx | Maintains: Buy | $84 → $100 | $79.02 | +26.55% | 4 | Nov 6, 2024 | |
| BHVN Biohaven | Maintains: Buy | $52 → $62 | $36.42 | +70.24% | 1 | Sep 24, 2024 | |
| RLAY Relay Therapeutics | Maintains: Buy | $20 → $24 | $4.45 | +439.33% | 1 | Sep 10, 2024 | |
| PROK ProKidney | Maintains: Neutral | $4 → $3 | $1.80 | +66.67% | 3 | Sep 4, 2024 | |
| PCVX Vaxcyte | Maintains: Buy | $101 → $140 | $85.78 | +63.21% | 3 | Sep 4, 2024 | |
| AXSM Axsome Therapeutics | Upgrades: Buy | $95 → $106 | $87.97 | +20.50% | 4 | Aug 6, 2024 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $67 → $68 | $36.33 | +87.17% | 5 | Jul 23, 2024 | |
| OCS Oculis Holding AG | Maintains: Buy | $21 → $20 | $17.07 | +17.16% | 3 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $21 | $22.62 | -7.16% | 12 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $82 → $91 | $86.00 | +5.81% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $41 → $31 | $27.38 | +13.22% | 6 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $11 | $0.18 | +5,990.81% | 3 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $21.91 | +4.97% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $29 | $29.81 | -2.72% | 9 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $37 | $19.53 | +89.45% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $56 | $39.48 | +41.84% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $34.72 | -13.59% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $51 | $25.73 | +98.21% | 3 | Dec 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $63 | $38.17 | +65.05% | 1 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 | $12.56 | -28.34% | 2 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $204 → $217 | $125.82 | +72.47% | 5 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $4 → $2 | $0.58 | +245.42% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $450 → $500 | $794.14 | -37.04% | 15 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $6 → $4 | $0.45 | +789.09% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 | $2.17 | +314.75% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $37 → $25 | $14.95 | +67.22% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $5 | $1.66 | +201.08% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $27 | $7.61 | +254.80% | 4 | Mar 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $20 | $1.49 | +1,242.28% | 1 | Jul 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $10 | $0.65 | +1,441.54% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $95 | $179.20 | -46.99% | 10 | May 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $58.00 | +3.45% | 7 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $37 | $26.56 | +39.31% | 4 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $90 | $99.87 | -9.88% | 11 | Oct 17, 2019 |
Exelixis
Dec 17, 2024
Downgrades: Neutral
Price Target: $35 → $39
Current: $34.03
Upside: +14.60%
bluebird bio
Nov 15, 2024
Downgrades: Neutral
Price Target: $60 → $10
Current: $8.78
Upside: +13.90%
Arcellx
Nov 6, 2024
Maintains: Buy
Price Target: $84 → $100
Current: $79.02
Upside: +26.55%
Biohaven
Sep 24, 2024
Maintains: Buy
Price Target: $52 → $62
Current: $36.42
Upside: +70.24%
Relay Therapeutics
Sep 10, 2024
Maintains: Buy
Price Target: $20 → $24
Current: $4.45
Upside: +439.33%
ProKidney
Sep 4, 2024
Maintains: Neutral
Price Target: $4 → $3
Current: $1.80
Upside: +66.67%
Vaxcyte
Sep 4, 2024
Maintains: Buy
Price Target: $101 → $140
Current: $85.78
Upside: +63.21%
Axsome Therapeutics
Aug 6, 2024
Upgrades: Buy
Price Target: $95 → $106
Current: $87.97
Upside: +20.50%
Ionis Pharmaceuticals
Jul 23, 2024
Maintains: Buy
Price Target: $67 → $68
Current: $36.33
Upside: +87.17%
Oculis Holding AG
Jun 11, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $17.07
Upside: +17.16%
May 30, 2024
Maintains: Buy
Price Target: $18 → $21
Current: $22.62
Upside: -7.16%
Apr 17, 2024
Maintains: Buy
Price Target: $82 → $91
Current: $86.00
Upside: +5.81%
Apr 1, 2024
Downgrades: Underperform
Price Target: $41 → $31
Current: $27.38
Upside: +13.22%
Mar 25, 2024
Maintains: Buy
Price Target: $12 → $11
Current: $0.18
Upside: +5,990.81%
Mar 7, 2024
Initiates: Buy
Price Target: $23
Current: $21.91
Upside: +4.97%
Jan 2, 2024
Maintains: Neutral
Price Target: $27 → $29
Current: $29.81
Upside: -2.72%
Jan 2, 2024
Maintains: Buy
Price Target: $29 → $37
Current: $19.53
Upside: +89.45%
Jan 2, 2024
Maintains: Buy
Price Target: $52 → $56
Current: $39.48
Upside: +41.84%
Jan 2, 2024
Downgrades: Underperform
Price Target: $30
Current: $34.72
Upside: -13.59%
Dec 21, 2023
Maintains: Buy
Price Target: $49 → $51
Current: $25.73
Upside: +98.21%
Nov 17, 2023
Initiates: Neutral
Price Target: $63
Current: $38.17
Upside: +65.05%
Oct 23, 2023
Downgrades: Underperform
Price Target: $9
Current: $12.56
Upside: -28.34%
Aug 10, 2023
Maintains: Buy
Price Target: $204 → $217
Current: $125.82
Upside: +72.47%
Aug 8, 2023
Downgrades: Underperform
Price Target: $4 → $2
Current: $0.58
Upside: +245.42%
May 24, 2023
Maintains: Buy
Price Target: $450 → $500
Current: $794.14
Upside: -37.04%
May 16, 2023
Maintains: Underperform
Price Target: $6 → $4
Current: $0.45
Upside: +789.09%
Dec 12, 2022
Downgrades: Underperform
Price Target: $9
Current: $2.17
Upside: +314.75%
Oct 14, 2022
Downgrades: Underperform
Price Target: $37 → $25
Current: $14.95
Upside: +67.22%
Dec 2, 2021
Downgrades: Underperform
Price Target: $45 → $5
Current: $1.66
Upside: +201.08%
Mar 24, 2021
Downgrades: Underperform
Price Target: $27
Current: $7.61
Upside: +254.80%
Jul 16, 2020
Initiates: Neutral
Price Target: $20
Current: $1.49
Upside: +1,242.28%
Jul 15, 2020
Downgrades: Neutral
Price Target: $17 → $10
Current: $0.65
Upside: +1,441.54%
May 18, 2020
Reinstates: Neutral
Price Target: $95
Current: $179.20
Upside: -46.99%
Oct 17, 2019
Reinstates: Buy
Price Target: $60
Current: $58.00
Upside: +3.45%
Oct 17, 2019
Reinstates: Neutral
Price Target: $37
Current: $26.56
Upside: +39.31%
Oct 17, 2019
Reinstates: Neutral
Price Target: $90
Current: $99.87
Upside: -9.88%